Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243412
Status:
COMPLETED
Last Update Posted:
2011-10-07
First Post:
2005-10-21
Brief Title:
A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Double-Blind Randomized Multicenter Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RUMBA
Brief Summary:
This was a Phase II randomized double-blind multicenter study designed to evaluate the safety and efficacy of rituximab administered at two different regimens for 2 years in patients with moderate to severe active rheumatoid arthritis RA receiving stable doses of methotrexate MTX
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None